trending Market Intelligence /marketintelligence/en/news-insights/trending/5tto4qgtqcfi9rzw-qgpow2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Apricus' erectile dysfunction drug launches in Lebanon

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Apricus' erectile dysfunction drug launches in Lebanon

Elis Pharmaceuticals Ltd. launched Apricus Biosciences Inc.'s erectile dysfunction drug in Lebanon.

The companies entered an agreement in 2011 to commercialize and market Vitaros in the Gulf States and part of the Middle East. The agreement yielded Apricus $100,000 in up-front payment and a further $100,000 after the drug was approved in Lebanon.

Apricus is eligible to receive up to a further $1.9 million in milestone-related payments for the product, which is approved in Canada and parts of Europe, Latin America and the Middle East.

Apricus will seek U.S. approval of the drug in 2017.